Odyssey buys drugmaker BenevolentAI in Europe’s largest-ever SPAC merger deal
On Monday, blank-check firm Odyssey had said in a statement that it had purchased British-based drugmaker BenevolentAI, valuing the pharmaceutical at £1.5 billion while marking off the largest-ever SPAC merger in Europe